Consolidated Financial Results for the Fiscal Year Ended March 31, 2026(Under Japanese GAAP)

May 7, 2026

Company name: Japan Lifeline Co., Ltd. Listing: Tokyo Stock Exchange Securities code: 7575

URL: https://www.japanlifeline.com/ Representative: Keisuke Suzuki, President and CEO

Inquiries: Takeyoshi Egawa, Director and Chief Financial Officer Telephone: +81-3-6711-5200

Scheduled date to hold ordinary general meeting of shareholders: June 26, 2026 Scheduled date to commence dividend payments: June 29, 2026

Scheduled date to file annual securities report: June 19, 2026 Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2026 (April 1, 2025-March 31, 2026)
   1. Consolidated operating results (Percentages indicate year-on-year changes.)

      	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent
      Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
      March 31, 2026	59,187	4.6	12,606	2.3	12,588	2.1	9,350	0.4
      March 31, 2025	56,610	10.2	12,326	13.2	12,335	16.6	9,317	24.0

      Note: Comprehensive income Fiscal year ended March 31, 2026: ¥9,552 million [(4.2)%]

      Fiscal year ended March 31, 2025: ¥9,971 million [22.0%]

      	Basic earnings per share	Diluted earnings per share	Return on equity	Return on assets	Operating profit margin
      Fiscal year ended	Yen	Yen	%	%	%
      March 31, 2026	133.30	133.28	14.9	16.2	21.3
      March 31, 2025	131.43	-	15.8	16.6	21.8

      Reference: Share of profit (loss) of entities accounted for using the equity method Fiscal year ended March 31, 2026: ¥－ million

      Fiscal year ended March 31, 2025: ¥－ million

   2. Consolidated financial position

      	Total assets	Total net assets	Equity ratio	Net assets per share
      As of	Millions of yen	Millions of yen	%	Yen
      March 31, 2026	80,211	65,897	82.1	938.65
      March 31, 2025	75,123	59,914	79.8	854.74

      Reference: Equity (Shareholders' equity + Accumulated other comprehensive income)

      As of March 31, 2026: ¥65,850 million As of March 31, 2025: ¥59,914 million

   3. Consolidated cash flows

   	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
   Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
   March 31, 2026	8,172	(2,048)	(4,581)	12,494
   March 31, 2025	9,113	(1,801)	(9,040)	11,014

2. Dividends

   	Annual dividends per share					Total dividends	Payout ratio (Consolidated)	Dividends on equity (Consolidated)
   	Q1-end	Q2-end	Q3-end	Year-end	Total
   Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026	Yen - -	Yen 0.00 0.00	Yen - -	Yen 53.00 54.00	Yen 53.00 54.00	Millions of yen 3,722 3,792	% 40.3 40.5	% 6.5 6.0
   Fiscal year ending March 31, 2027 (forecast)	-	0.00	-	56.00	56.00		49.1

3. Consolidated earnings forecast for the fiscal year ending March 31, 2027 (April 1, 2026-March 31, 2027)

(Percentages indicate year-on-year changes.)

• Notes

  1. Changes in significant subsidiaries (changes in specified subsidiaries resulting in changes in the scope of consolidation) during the period: None

  2. Changes in accounting policies, changes in accounting estimates, and restatement

     1. Changes in accounting policies due to revisions to accounting standards and other pronouncements: None

     2. Changes in accounting policies due to reasons other than (i): None

     3. Changes in accounting estimates: None

     4. Restatement: None

  3. Number of shares issued (common stock)

     1. Total number of shares issued at the end of the period (including treasury stock)

        As of March 31, 2026	71,300,000 shares
        As of March 31, 2025	75,758,470 shares

     2. Number of shares of treasury stock at the end of the period

        As of March 31, 2026	1,145,522 shares
        As of March 31, 2025	5,661,667 shares

     3. Average number of shares outstanding during the period

Note: The Company has adopted a Board Incentive Plan (BIP) trust, and the Company's shares held by the trust are included in the treasury stock deducted in the calculation of the number of shares of treasury stock at the end of the period and the average number of shares outstanding during the period.

1. Non-consolidated financial results for the fiscal year ended March 31, 2026 (April 1, 2025-March 31, 2026)
   1. Non-consolidated operating results (Percentages indicate year-on-year changes.)

      	Net sales		Operating profit		Ordinary profit		Net income
      Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
      March 31, 2026	59,187	4.6	12,669	3.5	12,635	3.3	9,434	1.7
      March 31, 2025	56,610	10.2	12,234	12.5	12,226	15.8	9,278	27.1

      	Basic earnings per share	Diluted earnings per share
      Fiscal year ended	Yen	Yen
      March 31, 2026	134.51	134.48
      March 31, 2025	130.88	-

   2. Non-consolidated financial position

   	Total assets	Net assets	Equity ratio	Net assets per share
   As of	Millions of yen	Millions of yen	%	Yen
   March 31, 2026	79,070	64,699	81.8	921.57
   March 31, 2025	74,197	58,743	79.2	838.03

   Reference: Equity (Shareholders' equity + Valuation and translation adjustments)

   As of March 31, 2026: ¥64,652 million As of March 31, 2025: ¥58,743 million

2. Non-consolidated earnings forecast for the fiscal year ending March 31, 2027 (April 1, 2026-March 31, 2027)

(Percentages indicate year-on-year changes.)

• Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

• Proper use of earnings forecast, and other special matters

  The forward-looking statements including earnings forecasts contained in this document are based on information currently available to the Company and certain assumptions that are deemed to be reasonable. Accordingly, the Company does not guarantee the achievement of the forecast, and actual results may differ significantly from the forecast due to various factors. For the assumptions for earnings forecasts and cautions concerning the use thereof, please refer to "1. Overview of Financial Performance, (4) Outlook" on page 7 of the attached materials.

  Contents of Attached Materials

  1. Overview of Financial Performance ..................................................................................................................................... 2

     1. Operating results ............................................................................................................................................................. 2

     2. Financial position............................................................................................................................................................ 6

     3. Cash flows ...................................................................................................................................................................... 6

     4. Outlook ........................................................................................................................................................................... 7

  2. Basic Policy on the Selection of Accounting Standards ....................................................................................................... 8

  3. Consolidated Financial Statements and Major Notes ........................................................................................................... 9

     1. Consolidated balance sheets............................................................................................................................................ 9

     2. Consolidated statements of income and consolidated statements of comprehensive income.......................................... 11

     3. Consolidated statements of changes in equity................................................................................................................. 13

     4. Consolidated statements of cash flows............................................................................................................................ 15

     5. Notes to consolidated financial statements ..................................................................................................................... 16

        Going concern assumption ........................................................................................................................................... 16

        Segment information, etc. ............................................................................................................................................. 16

        Per share information................................................................................................................................................... 16

        Significant Subsequent events....................................................................................................................................... 16

  4. Other..................................................................................................................................................................................... 17

     1. Status of production, orders received and sales............................................................................................................... 17

     2. Changes in board members ............................................................................................................................................. 17

- 1 -

1. Overview of Financial Performance

   1. Operating results

Forward-looking statements below are based on our judgment at the end of the current fiscal year.

Business environment

Japan Lifeline is engaged mainly in the manufacture and sales of highly controlled medical devices, primarily focusing on cardiac devices, for general hospitals in Japan.

The business environment surrounding Japan's medical devices industry is characterized by the three main dynamics of 1) expanding structural demand driven by increase in the elderly population, 2) strained medical care delivery system, and 3) changes in the macroeconomy such as weak yen and inflation, and they are having an increasingly significant impact on the performance of individual companies. In this environment, medical trends in the market have been constantly changing and the demand for efficient and relevant solutions to various challenges faced by medical professionals have been increasing more than ever.

First, on the demand side, the market continues to expand against the backdrop of the increase in the elderly population. In particular, the number of atrial fibrillation cases in the cardiovascular field has continued to increase at a strong pace since the mid-2010s. Further, with the number of people aged 75 and older increasing significantly from 2025, the shift from surgeries to less physically taxing endovascular therapy (minimally invasive treatment) is also expected to gather pace. As minimally invasive treatment will gradually lower the age of eligible patients, it will lead to expansion of the medical device market, and provide a tailwind for the industry. We expect such structural expansion in demand to form a base that supports market growth in the future.

Secondly, chronic shortage of resources at medical institutions, which are on the supply side of medical care, has become a serious issue. Given the shortened working hours and staff shortage following workstyle reform of doctors, there is strong

demand for medical devices that support streamlining of medical care including simplification of procedures and shortening of treatment time in a clinical environment. This is not just about the pursuit of therapeutic effects but signals that we are now moving into an era where products that succeed will be the ones contributing toward sustaining the medical care delivery

system.

Thirdly, in terms of macroeconomy, the weakening of the yen and the worldwide inflation could also have an impact on our profit structure. Even as manufacturing expenses including raw material costs, logistics costs, and labor costs as well as selling, general and administrative expenses are increasing, it is difficult for us to pass on the rise in such costs immediately to the

selling prices as the official prices of medical devices are set by the government under Japan's universal healthcare system. For that reason, we need to continuously monitor inflation as a risk that could put pressure on our profits.

In light of the above recognition of the environment, our important management challenges include diversifying domestic risk by expanding the business globally and implementing appropriate growth strategies to address the changes in the medical care trends. As for globalization, our urgent tasks are optimizing domestic products for the overseas market and establishing global quality standards. In terms of addressing the changes in the medical care trends, R&D related to pulsed field ablation (PFA) for arrhythmia treatment and the acquisition of pipeline assets such as stent graft and transcatheter aortic valve implantation

(TAVI) for endovascular therapy are examples of our efforts to capture the opportunity. We aim to achieve both sustainable growth and profitability in this rapidly changing business environment through early incorporation of market needs into our product lineup, leveraging the unique hybrid business model combining our dual roles of manufacturer and distributor.

- 2 -